Clinical TrialMay 5, 2026, 08:07 AM
Compass Therapeutics Tovecimig Phase 2/3 BTC Study Meets Primary Endpoint
AI Summary
Compass Therapeutics announced positive Phase 2/3 study results for Tovecimig in biliary tract cancer, meeting its primary endpoint of overall response rate and showing significant improvement in progression-free survival. The company also received Orphan Drug Designation from the FDA for Tovecimig in BTC. For Q1 2026, Compass Therapeutics reported a net loss of $18.3 million, an increase from $16.6 million in Q1 2025, with cash and marketable securities of $195 million expected to fund operations into 2028.
Key Highlights
- Tovecimig Phase 2/3 BTC study achieved 17.1% ORR vs 5.3% for paclitaxel alone (p=0.031).
- Median Progression-Free Survival (PFS) was 4.7 months vs 2.6 months (HR=0.44, p<0.0001).
- Tovecimig received Orphan Drug Designation from the FDA for biliary tract cancer.
- Net loss for Q1 2026 was $18.3 million, compared to $16.6 million in Q1 2025.
- Research and development expenses increased to $13.39 million from $13.05 million YoY.
- General and administrative expenses rose to $6.91 million from $4.91 million YoY.
- Cash, cash equivalents, and marketable securities totaled $195 million as of March 31, 2026.
- Company expects current cash resources to fund operations into 2028.
Price Impact
More from CMPX